NEDOSIRAN SODIUM | NOVO | ||
EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML),EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML),EQ 160MG BASE/ML (EQ 160MG BASE/ML) | |||
No | No | ||
2038-Oct-12 | 2028-Sep-29 | ||
None | None | ||
None | No | ||
RIVFLOZA is an LDHA-directed small interfering RNA indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥ 30 mL/min/1.73 m2. |
0 | 0 | 0 |
Total Other Developers | None |
---|
Drugs with Suitability | No |
---|
EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML) | ** | ** | - | - | - |
EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML) | ** | ** | - | - | - |
EQ 160MG BASE/ML (EQ 160MG BASE/ML) | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
No | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com